

# Role of Cerebral Imaging on Diagnosis and Management in Patients With Suspected Infective Endocarditis

Matthaios Papadimitriou-Olivgeris,<sup>1,®</sup> Benoit Guery,<sup>1</sup> Nicoleta Ianculescu,<sup>2</sup> Vincent Dunet,<sup>3</sup> Yosra Messaoudi,<sup>2</sup> Silvia Pistocchi,<sup>3</sup> Piergiorgio Tozzi,<sup>4</sup> Matthias Kirsch,<sup>4</sup> and Pierre Monney<sup>2</sup>

<sup>1</sup>Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland; <sup>2</sup>Department of Cardiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland; <sup>3</sup>Department of Medical Radiology, Service of Diagnostic and Interventional Radiology, Neuroradiology Unit, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland; and <sup>4</sup>Department of Cardiac Surgery, Lausanne University Hospital and University of Lausanne, Switzerland

Background. Cerebral embolic events (CEEs) are common complications of infective endocarditis (IE), and their presence can modify diagnosis and therapeutic plans. The aim of the present study was to assess the role of cerebral imaging (Cer-Im) on diagnosis and management of patients with suspected IE.

Methods. This study was conducted at the Lausanne University Hospital, Lausanne, Switzerland, from January 2014 to June 2022. CEEs and IE were defined according to modified Duke criteria of the European Society of Cardiology (ESC) guidelines.

Results. Among 573 patients with IE suspicion and Cer-Im, 239 (42%) patients had neurological symptoms. At least 1 CEE was found in 254 (44%) episodes. Based on Cer-Im findings, episodes were reclassified from rejected to possible or from possible to definite IE in 3 (1%) and 25 (4%) patients, respectively (0% and 2% in asymptomatic patients, respectively). Among the 330 patients with possible or definite IE, at least 1 CEE was found in 187 (57%) episodes. A new surgical indication (in association with left-side vegetation >10 mm) was established in 74/330 (22%) IE patients and 30/155 (19%) asymptomatic IE patients, respectively.

Conclusions. Cer-Im in asymptomatic patients with IE suspicion showed limited potential for improving the diagnosis of IE. In contrast, performing Cer-Im in asymptomatic patients with IE may be useful for decision making, because Cer-Im findings led to the establishment of new operative indication for valvular surgery in one fifth of patients according to ESC guidelines.

Keywords. infective endocarditis; MRI; embolization; ischemic lesions; valve surgery.

Despite advances in diagnostic imaging and more aggressive treatment strategies, infective endocarditis (IE) remains a lifethreatening condition associated with high in-hospital mortality (15%-30%) [1]. One of the most common complications contributing to the increased mortality is embolization, especially to the central nervous system, which is the most common site associated with embolic events (EEs) [2, 3]. Cerebral EEs (CEEs) have previously been associated with large vegetations and mitral valve involvement [4-6].

The most common CEEs are ischemic lesions, followed by hemorrhagic strokes, mycotic aneurysms and cerebral abscesses [4, 6-9]. Although many EEs to the central nervous system

#### Clinical Infectious Diseases<sup>®</sup> 2023:77(3):371-9

are symptomatic (neurologic deficit, confusion, seizures, headache), studies with systematic cerebral imaging studies (Cer-Im) found that the majority of CEEs are asymptomatic [2, 10-14]. Identification of CEEs can contribute to make the diagnosis of IE, since vascular phenomena are part of the minor Duke criteria [15]. Additionally, the presence of CEEs in patients with left-side valvular vegetations >10 mm is an indication for urgent valve surgery according to the 2015 European Society of Cardiology (ESC) guidelines in order to prevent subsequent embolism [15]. In a metanalysis of studies, where cerebral MRI was systematically performed, Cer-Im findings led to a change of treatment strategy in 13% and contributed to valvular surgery planification in 14% of patients [16].

Although many previous studies already evaluated the impact of Cer-Im on IE diagnosis and modification of the therapeutic strategy, most of them only included limited number of patients [16]. Furthermore, all but one studies exclusively included patients with a final diagnosis of IE (definite or possible) [2, 3, 13, 16], and the only study assessing the role of Cer-Im in suspected IE only included 60 patients [5]. Therefore, we aimed to describe the frequency of symptomatic and asymptomatic CEEs by Cer-Im in a large cohort of patients with suspected or confirmed IE and to determine the impact of such findings on diagnosis and management.

Received 10 January 2023; editorial decision 28 March 2023; published online 31 March 2023

Correspondence: M. Papadimitriou-Olivgeris, Infectious Diseases Service, Lausanne University Hospital, Rue du Bugnon 46, 1011 Lausanne, Switzerland (Matthaios. Papadimitriou-Olivgeris@chuv.ch).

<sup>©</sup> The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/). which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com https://doi.org/10.1093/cid/ciad192

# METHODS

# **Study Design**

This study was conducted at the Lausanne University Hospital, Lausanne, Switzerland, a 1100-bed primary and tertiary care hospital from January 2014 to June 2022 (2014–17: retrospective cohort; 2018 onward: prospective cohort). The study was approved by the ethics committee of the Canton of Vaud (CER-VD 2017–02137).

# Patients

For the prospective cohort, the inclusion criteria were adult patients ( $\geq$ 18 years old) with clinical suspicion of IE (patients who had blood cultures drawn and an echocardiography performed specifically for the research of IE), Cer-Im realization (computed tomography [CT] scan or magnetic resonance imaging [MRI]) and written consent. For the retrospective cohort, the inclusion criteria were adult patients ( $\geq$ 18 years old) with possible or definite IE, Cer-Im realization, and absence of refusal of the use of their clinical data.

Data regarding demographics (age, sex), comorbidities, cardiac predisposing factors [15], microbiologic etiology, systemic symptoms, fever, acute heart failure, sepsis or septic shock, heart murmur, immunological phenomena [15], site of cardiac involvement and type of lesion (according to cardiac imaging modalities, macroscopic lesions on surgery or autopsy), cardiac surgery (timing), results of thoracoabdominal and cerebral imaging studies (timing, results) and embolic events (type, timing, symptoms) were retrieved from patients' electronic health records.

# Management of IE

According to internal guidelines, an infectious diseases consultation with a thorough physical examination was performed on a mandatory basis for all patients with a suspicion of IE. Thoracoabdominal and Cer-Im were performed in all patients with local symptoms; their realization in asymptomatic patients was at the discretion of the treating physician and infectious diseases consultant. An endocarditis-team was established on January 2018, comprising of infectious diseases specialists, cardiologists, cardiac surgeons, which reviewed all patients with IE suspicion during weekly meetings. Furthermore, in our center, valve surgery was proposed to patients with a vegetation >10 mm and EEs even if the EEs occurred before 5 days of appropriate antimicrobial treatment; the decision was validated for each individual patient by the endocarditis team.

# Definitions

IE was defined according to the modified Duke criteria [15]. IE was characterized as community, healthcare, or nosocomial according to Friedman et al [17]. EEs were defined as septic lung emboli, renal or splenic emboli, mycotic aneurysm, intracranial ischemia or bleeding, cerebral abscess, conjunctival bleeding,

retinal emboli, chorioretinitis, Janeway lesions or nail bed bleeding, and peripheral major vascular emboli.

# **Cerebral Imaging Results**

A patient was considered symptomatic in the presence of neurologic deficit, confusion, coma, headache or seizures; the absence of all aforementioned symptoms categorized the patient as asymptomatic. CEEs detected by Cer-Im included ischemic brain lesions, intracranial bleeding, cerebral mycotic aneurysm, or abscess.

# Impact of Cerebral Imaging

IE was classified according to the modified Duke criteria assessed at day 60, based on clinical, microbiological, imaging, surgical data or autopsy results (final diagnosis). A separate Duke classification was established blinded to the results of Cer-Im. Based on these 2 assessments, the rate of diagnostic reclassification (from rejected to possible and from possible to definite IE) was calculated for the whole cohort and in the subgroup of patients with a final diagnosis of possible or definite IE.

The changes in management due to Cer-Im were calculated among patients with possible or definite IE. The impact on management was defined as the establishment of a new indication for valve surgery and, subsequently, the effective performance of valvular surgery. Other interventions related to CEE included intravenous thrombolysis or endovascular thrombectomy for ischemic lesions, drainage of abscess or specific treatment of hemorrhagic lesions or mycotic aneurysms. Intravenous thrombolysis for ischemic lesions is contraindicated in IE patients [15]; it was performed in few patients because the suspicion of IE was substantiated only later.

# Analysis

SPSS version 26.0 (SPSS, Chicago, Illinois, USA) software was used for data analysis. Categorical variables were analyzed using the  $\chi^2$  or Fisher exact test and continuous variables with Mann-Whitney *U* test. Bivariate and multivariable logistic regression analyses were performed with dependent variable being CEEs found on Cer-Im in patients with IE suspicion and those with IE. Variables with *P* < .1 that did not contribute to multicollinearity (variance inflation factor assessment) were used in multivariable analyses. Adjusted odds ratios (aORs) and 95% confidence intervals (CIs) were calculated to evaluate the strength of any association. All statistic tests were 2-tailed, and *P* < .05 was considered statistically significant.

# RESULTS

# **Study Population**

Among the 1259 episodes of the prospective cohort, 456 had a Cer-Im and were thus included (Figure 1). Out of the 190 episodes of the retrospective cohort, 117 had a Cer-Im and were included. In total, 573 episodes with suspected IE were included, and 330 (58%) episodes had possible of definite IE (definite





IE: 278, possible: 52). For the remaining 243 (42%) episodes, the final diagnosis included other type of infection (175; 72%), stroke (24; 10%), and other diagnoses (44; 18%).

### **Cerebral Imaging in Patients With Suspected Infective Endocarditis**

Among 573 episodes, 343 (60%) benefited from CT scan (265; 77% with contrast media) and 343 (60%) from MRI; 113 (20%) benefited from both CT and MRI (63 among them within 24 hours). The median time from IE suspicion to Cer-Im was 2 days (Q1–Q3: 1–6). Most of the episodes with Cer-Im were symptomatic (334; 58%) with the most frequently observed

symptoms and signs being confusion or coma (178; 53%) and neurologic deficit (143; 43%).

At least 1 CEE was found on Cer-Im in 254 (44%) episodes (Table 1). Ischemic lesions were the most commonly identified lesions (n = 251; 99%), followed by hemorrhagic lesions (n = 40; 14%). The comparison between cerebral CT and MRI for the detection of specific CEEs is shown in Supplementary Table 1. For 74 (13%) episodes, the Duke's vascular criterion was already fulfilled prior to the realization of the Cer-Im. Thus, 180 (31%) episodes met the vascular criterion due to the Cer-Im; 3 (1%) episodes were reclassified from rejected to

# Table 1. Type of Cerebral Embolic Events and Their Impact on Diagnosis and Management in Patients With Suspected Infective Endocarditis

	Total	(n = 573)	Asym (n :	ptomatic = 239)	Symı (n	otomatic = 334)	P*
MRI	343	60%	124	52%	219	66%	.001
No cerebral embolic event	319	56%	172	72%	147	44%	
Cerebral embolic event	254	44%	67	28%	187	56%	<.001
Ischemic lesions	251	44%	66	28%	185	55%	.001
Intravenous thrombolysis <sup>a</sup>	12	4%	0	0%	12	4%	.002
Endovascular thrombectomy	17	3%	0	0%	17	5%	<.001
Hemorrhagic lesions	40	7%	7	3%	33	10%	.001
Treatment of hemorrhagic lesions	1	<0.5%	0	<0.5%	1	<0.5%	1.000
Mycotic aneurysm	18	3%	7	3%	11	3%	1.000
Treatment of mycotic aneurysm	3	1%	0	0%	3	1%	.269
Cerebral abscess	12	2%	2	1%	10	3%	.084
Drainage of abscess	6	1%	0	0%	6	2%	.044
Treatment of any cerebral embolic event	33	6%	0	0%	33	10%	<.001
New cerebral embolic event <sup>b</sup>	180	31%	39	16%	141	42%	<.001
Reclassification from rejected to possible endocarditis	3	1%	0	0%	3	1%	.269
Reclassification from possible to definite endocarditis	25	4%	4	2%	21	6%	.007

Data are depicted as number/percentage.

Abbreviation: MRI, magnetic resonance imaging.

\*Comparison between symptomatic and asymptomatic patients.

<sup>a</sup>Thrombolysis was performed in patients for which the infective endocarditis (IE) suspicion was not substantiated the moment of the decision.

<sup>b</sup>Not prior cutaneous, ocular, or thoracoabdominal embolic event



Figure 2. Changes in diagnostic classification management due to cerebral imaging results in patients suspected (A) and those with infective endocarditis (B). Abbreviations: CEE, cerebral embolic event; Cer-Im, cerebral imaging; EE, embolic event; IE, infective endocarditis.

possible IE and 25 (4%) from possible to definite IE according to modified Duke criteria (Figure 2). Among the 239 asymptomatic episodes, the vascular criterion was fulfilled by the Cer-Im in 39 (16%) episodes; no episode was reclassified from rejected to possible and 4 (2%) episodes from possible to definite IE. In 33 (6%) out of 573 episodes an intervention was directed toward the CEEs found on Cer-Im, none among 239 asymptomatic episodes (Table 1).

The comparison of episodes with and without EE on Cer-Im is shown on Table 2. In the multivariable analysis (Supplementary Table 2), the factors associated with the presence of CEE on Cer-Im included final IE diagnosis (P < .001; aOR 12.4, 95% CI: 6.64–23.2) and presence of neurologic symptoms (P < .001; aOR 5.02, 95% CI: 3.27–7.71), whereas presence of ocular EE prior to Cer-Im (P < .072; aOR 2.47, 95% CI: .92–6.62) and positive imaging Duke criterion (P < .113; aOR 1.59, 95% CI: .90–2.81) had no significant association with CEE discovery on Cer-Im.

# **Cerebral Imaging in Patients With Infective Endocarditis**

Among the 330 episodes with possible or definite IE, the median time from antibiotic treatment initiation to Cer-Im was 2 days (Q1–Q3: 0–5). In 175 (53%) the Cer-Im was performed in the absence of any neurologic symptom. At least 1 CEE was found on Cer-Im in 187 (57%) episodes (Table 3). Ischemic lesions (184; 98%) were the most commonly identified, followed by hemorrhagic lesions (35; 19%). For 67 (20%) episodes, the Duke's vascular criterion was fulfilled prior to the realization of the Cer-Im. Thus, 120 (36%) episodes met the vascular criterion due to the Cer-Im; 3 (1%) episodes were reclassified from rejected to possible IE and 25 (8%) episodes from possible to definite IE according to modified Duke criteria (Figure 2). Among episodes without neurologic symptoms, the vascular criterion was fulfilled by the Cer-Im in 34 (22%) episodes, leading to the reclassification of the episode from possible to definite IE in 4 (3%) episodes. A new surgical indication (in association with left-side vegetation >10 mm) for embolism prevention was established by the Cer-Im findings in 74 (22%) episodes (55 had valve surgery), 30 of which were asymptomatic (27 had valve surgery) (Table 3). The median time from Cer-Im to surgical intervention was 4 days (Q1–3: 1–14). Among the 19 episodes with a surgical indication, which did not receive valvular operation, surgery was contraindicated in 3 of them due to coma and in 1 due to hemorrhagic lesion.

Additional analyses were performed among 194 and 185 IE episodes, which had cerebral MRI and CT, respectively (Supplementary Tables 3 and 4). Among patients having MRI, 3 (2%) episodes were reclassified from rejected to possible IE and 17 (9%) from possible to definite IE. A new surgical indication (in association with left-side vegetation >10 mm) was established by the MRI findings in 53 (27%) episodes (40 had valve surgery), 18 of which were asymptomatic (14 had valve surgery).

The comparison of episodes with and without CEE are shown in Table 4. In the multivariable analysis (Supplementary Table 5), the factors associated with CEEs were mitral valve IE (P.002; aOR 2.27, 95% CI: 1.38–3.74), intracardiac abscess (P.003; aOR 1.89, 95% CI: 1.05–3.39), presence of neurologic symptoms (P < .001; aOR 4.36, 95% CI: 2.67–7.14), and presence of ocular EE prior to Cer-Im (P.036; aOR 5.60, 95% CI: 1.12–28.17).

#### DISCUSSION

In the present study, performing Cer-Im in the diagnostic workup of patients with suspected IE resulted in the discovery of

# Table 2. Predictors of Embolic Events Detected by Cerebral Imaging Among Patients With Suspected Infected Endocarditis

	Without 0	CEE (n = 319)	With CE	Р	
Demographics					
Male sex	226	71%	174	69%	.583
Age (y)	67	49–75	67	53–76	.885
Comorbidities					
Atrial fibrillation	71	22%	47	19%	.299
Congestive heart failure	36	11%	16	6%	.041
Chronic obstructive pulmonary disease	50	16%	31	12%	.278
Cirrhosis	32	10%	14	6%	.062
Diabetes mellitus	82	26%	52	20%	.162
Chronic kidney disease (moderate or severe)	54	17%	36	14%	.419
Malignancy (solid organ or hematologic)	61	19%	27	11%	.005
Obesity	85	27%	54	21%	.142
Immunosuppression	52	16%	24	9%	.018
Antithrombotic or anticoagulation treatment	147	46%	124	49%	.556
Antithrombotic treatment	86	27%	71	28%	.851
Anticoagulation treatment	80	25%	64	25%	1 000
Cardiac predisposing factors	97	30%	103	41%	013
Prosthetic valve	47	15%	61	24%	.015
Bacteremia	256	80%	183	72%	023
Stanbylococcus aureus	128	41%	81	34%	112
	18	6%	6	3%	.112
Strentococci	56	18%	61	26%	.001
Enterococci	27	0%	21	2076	1 000
Other gram positive	10	3 /0	21	3 78 1 9/	1.000
	10	1.0/	5	170	.100
Other gram negative	21	7%	5	2 /8	.300
	10	7 70	0	3 70	.020
Puligi Delumierskiel besteremie	10	5 %	3	1 70	.100
Polymicrobial bacteremia	10	D %0	3	1 %	.017
Customic executions	204	000/	202	00.0/	002
Systemic symptoms	284	89%	203	80%	.003
	259	81%	176	69%	.001
Heart murmur	135	42%	124	49%	.129
New heart murmur	88	28%	96	38%	.012
Immunologic phenomena	14	4%	27	11%	.005
Sepsis	125	39%	111	44%	.305
Septic shock	44	14%	45	18%	.204
Cerebral imaging performed due to neurologic symptoms	147	46%	187	74%	<.001
Deficit	28	9%	115	45%	<.001
Confusion/coma	94	29%	84	33%	.365
Headache	22	7%	24	9%	.282
Seizures	2	1%	6	2%	.147
Days to cerebral imaging	3	1–7	1	0–4	<.001
Embolic events prior to cerebral imaging	79	25%	74	29%	.255
Cutaneous	13	4%	17	7%	.188
Ocular	9	3%	15	6%	.092
Thoracoabdominal	63	20%	61	24%	.222
Infective endocarditis (final diagnosis)	143	45%	187	74%	<.001
Positive Duke imaging criterion	121	38%	167	66%	<.001

Data are depicted as number/percentage or median/Q1–Q3.

Abbreviations: CEE, cerebral embolic events; HACEK, Haemophilus spp., Aggregatibacter spp., Cardiobacterium hominis, Eikenella corrodens, Kingella kingae.

CEEs in 44% of cases, but their identification had limited impact on the final diagnosis of IE. However, CEE detection frequently influenced subsequent surgical management, with 22% of IE patients meeting a new surgical indication following Cer-Im findings. To the best of our knowledge, this study is the largest to date trying to elucidate the role of Cer-Im in the diagnosis and subsequent management of patients with suspected IE.

As previously shown, the central nervous system was the most common site of embolization among patients with definite or possible IE. In fact, 57% of patients had a CEE, which

#### Table 3. Type of Cerebral Embolic Events and Impact on Diagnosis and Management in Patients With Infective Endocarditis

	Total (n = 330)		Asymptomatic (n = 155)		Symptomatic (n = 175)		P*
MRI	194	59%	78	50%	116	66%	.004
No cerebral embolic event	143	43%	95	61%	48	27%	
Cerebral embolic event	187	57%	60	39%	127	73%	<.001
Ischemic lesions	184	56%	59	38%	125	71%	<.001
Intravenous thrombolysis <sup>a</sup>	5	2%	0	0%	5	3%	.063
Endovascular thrombectomy	11	3%	0	0%	11	6%	.001
Hemorrhagic lesions	35	11%	7	5%	28	16%	.001
Treatment of hemorrhagic lesions	1	<0.5%	0	0%	1	1%	1.000
Mycotic aneurysm	18	6%	7	5%	11	6%	.629
Treatment of mycotic aneurysm	2	1%	0	0%	2	1%	.500
Cerebral abscess	6	2%	2	1%	4	2%	.688
Drainage of abscess	0	0%	0	0%	0	0%	
Treatment of any cerebral embolic event	15	5%	0	0%	15	9%	<.001
New cerebral embolic event <sup>b</sup>	120	36%	34	22%	86	49%	<.001
Reclassification from rejected to possible endocarditis	3	1%	0	0%	3	2%	.250
Reclassification from possible to definite endocarditis	25	8%	4	3%	21	12%	.001
Operative indication <sup>c</sup>	74	22%	30	19%	44	25%	.235
Valvular surgery performed	55	17%	27	17%	28	16%	.768

Data are depicted as number/percentage.

Abbreviation: MRI, magnetic resonance imaging.

\*Comparison between symptomatic and asymptomatic patients.

<sup>a</sup>Thrombolysis was performed in patients for which the infective endocarditis (IE) suspicion was not substantiated the moment of the decision.

<sup>b</sup>Not prior cutaneous, ocular, or thoracoabdominal embolic event.

<sup>c</sup>In association with left-side valvular vegetation >10 mm.

was more common among symptomatic (73%) as compared to asymptomatic patients (39%). Previous studies reported wide variations in the prevalence of CEEs (22%–83%) [2, 4, 5, 7–14]. This wide range of incidence among previous studies was due the difference of inclusion criteria. Studies with higher incidence of reported CEEs included patients with neurologic symptoms [7], definite IE [4, 7, 9–11], with MRI [2, 7, 9–14], or Cer-Im performed as pre-operative screening [7–9].

The prevalence of CEEs (39%) among asymptomatic IE patients was significantly higher than previously reported (4%–30%) [4, 5, 8], whereas some studies presented higher rates (60%–80%) [2, 10–14]. These wide differences in prevalence may be explained by the various definitions of symptomatic lesions. Most studies defined lesions as symptomatic only in presence of focal neurologic deficit [4, 5, 11] but not in the presence of confusion, seizures, or headache as was the case for the present study. Therefore, our wider definition of neurologic symptoms may explain a higher prevalence of symptomatic CEE and a lower prevalence of asymptomatic CEE compared to previous studies.

The majority of CEEs were ischemic lesions (98%), which is in accordance to most previous studies [4, 6-9]. The few previous studies, which reported hemorrhagic lesions as the most common ones, also included microbleeds in the definition of hemorrhagic CEE, which was not the case in the present study [2, 10-13]. In a previous study, microbleeds presence was not associated with typical risk factors of embolization, such as vegetation size or type of pathogen, and showed a weak concordance with the presence of ischemic lesions, suggesting a difference process [13]. The results of our study were in line with a metanalysis including IE patients with cerebral MRI, which also identified ischemic lesions as the most common type of CEE. In all studies, mycotic aneurysms and abscesses were present on a minority of patients [6, 7, 10–13, 18].

Imaging studies for embolic events (cerebral MRI, whole body CT and/or <sup>18</sup>F-FDG PET-CT) were part of the diagnostic algorithm in patients with a high clinical suspicion but still unproven IE, according to the ESC guidelines [15]. The role of cerebral MRI in diagnostic reclassification was previously studied among IE patients, and the results of cerebral MRI was found to lead to a change in classification in 5%–32% of patients [2, 3, 13]. In the present study, which is the only 1 having included patients with suspected IE and not only patients with an established diagnosis of IE, Cer-Im findings allowed diagnostic reclassification in 5% of patients only (1% among asymptomatic patients). Among 343 patients who benefited from MRI, diagnostic reclassification was also low. According to our results, there is little reason to recommend systematic Cer-Im for diagnostic purposes in asymptomatic patients with suspected IE.

Another potential impact of Cer-Im on patients with suspected IE, is the possibility to offer a specific treatment of

# Table 4. Predictors of Embolic Events Detected by Cerebral Imaging Among Patients With Infective Endocarditis

Demographics         View		Without C	CEE (n = 143)	With CEE (n = 187)		Р
Mole six         108         76%         137         73%         610           Age M         66         48-74         07         66-75         388           Cancendidias         3         22         39         21%         398         21%         393         21%         393         21%         393         21%         393         21%         393         21%         393         21%         393         21%         393         31         3%%         306         27%         394         41%         30%         30         21%         305         22%         393         26%         303         2%         303         2%         306         3	Demographics					
Age My         65         48-74         67         58-75         388           Atter fichalition         32         22%         39         21%         .777           Atter fichalition         32         22%         39         21%         .778           Chronic bottractive pulmonary disease         19         13%         22         12%         .749           Distances mailtus         43         30%         43         22%         .749         .749           Distances finance (moderate or awerer)         18         13%         20         .75%         .863           Maignaney (Socia oran or hematologic)         14         10%         14         .7%         .863           Anticromotic or anticoagulation treatment         44         31%         51         .27%         .843           Anticromotic or anticoagulation treatment         44         .31%         .51         .27%         .843           Anticromotic or anticoagulation treatment         44         .31%         .51         .27%         .843           Anticromotic or anticoagulation treatment         44         .31%         .51         .27%         .843           Anticromotic or anticoagulation treatment         .43         .30%         .	Male sex	109	76%	137	73%	.610
Chronibolities         Section         Secon         Section         Section	Age (y)	65	48–74	67	55–75	.358
Athin finalitation         32         22%         39         21%	Comorbidities					
Congestive heart failure         18         13%         11         6%         .045           Chronic isbattwine putmonsky disease         13         9%         11         6%         .290           Chronic isbattwine putmonsky disease (moderate or severe)         18         13%         28         .15%         .031           Malignancy Isolid organ or hematologic)         14         10%         14         7%         .851           Obesity         39         2.7%         37         2.0%         .11         .5%         .811           Anthromototic treatment         12         8%         14         7%         .838           Anthromototic treatment         41         31%         51         .27%         .510           Anthromototic treatment         13         9%         14         .8%         .828           Cardiac predisposing factors         74         52%         .84         .89%         .828           Tornal of the treatment         10         9%         14         .8%         .828           Tornal of the treatment reatment         .64         45%         .77         .843         .27%           2015-2017 interspactive schort         .60         .3%         .32%         .3	Atrial fibrillation	32	22%	39	21%	.787
Chronic obstructive pulmonary disease         19         13%         22         12%         7.47           Chronic is obstructive pulmonary disease         43         90%         43         23%         .165           Diabetes mellina         43         90%         43         23%         .165           Chronic kichney disease imoderate or severel         18         13%         28         .175         .031           Maligrancy (stald organ or hematologic)         14         10%         14         .7%         .031           Obesity         39         27%         37         20%         .115           Immunosuppression         12         8%         14         .7%         .893           Antichomobic ir entreament         44         30%         .60         .27%         .538           Chronic kind in entreament         43         30%         .60         .825         .538           Cardiac predipation factors         74         62%         .94         .60%         .633           Cardiac predipacing factors         74         62%         .67         .38         .29           2018202 (not sepacitive schorth         50         .55%         .67         .38         .29 <t< td=""><td>Congestive heart failure</td><td>18</td><td>13%</td><td>11</td><td>6%</td><td>.048</td></t<>	Congestive heart failure	18	13%	11	6%	.048
Cirnosis         13         9%         11         6%         290           Debastar millsa         43         30%         43         23%         .05%           Malignancy Isolid organ or hematological         14         10%         14         7%         .831           Malignancy Isolid organ or hematological         14         10%         14         7%         .831           Antifromotic or ancoaquitation treatment         12         8%         14         7%         .838           Antifromotic or ancoaquitation treatment         13         30%         50         .27%         .530           Antifromotic or neasonal hearthcare-associated         33         27%         .57         .30%         .640           Contrantly or non-assocomal hearthcare-associated         33         27%         .57         .30%         .543           Timing of I         2015-2017 (retrospective cohort)         50         .55         .67         .36         .321           Statist of Inflation         13         9%         14         .57%         .543         .27%         .30%         .543         .27%         .30%         .543         .27%         .30%         .53         .32%         .300         .3174         .32%	Chronic obstructive pulmonary disease	19	13%	22	12%	.747
Debases mellica         43         30%         44         22%         166           Chronic kidny disses (indication or severe)         18         13%         28         15%         631           Malignancy (isolid organ or hematologic)         14         10%         14         7%         653           Density         39         27%         37         20%         115           Immunosportscion         12         8%         14         7%         638           Antthromotic or anticogulation treatment         13         30%         50         27%         504           Antitocomotic or networts         130         91%         173         93%         64           Community or non-necocomial healthcare-associated         130         91%         173         93%         63           Consolidion freatment         13         8%         14         8%         688           Cardiac predopoing fractor         71         12%         93%         63         20%         63           2015-2022 (prospective colort)         59         36         129         42         908           2015-2022 (prospective colort)         59         36%         129         43%         30         31 </td <td>Cirrhosis</td> <td>13</td> <td>9%</td> <td>11</td> <td>6%</td> <td>.290</td>	Cirrhosis	13	9%	11	6%	.290
Dronic kidney disease (moderate or severe)         18         13%         28         15%         633           Desity         33         27%         37         20%         1.115           Inmunoscopression         12         8%         14         7%         633           Antithomobic reatment         14         31%         51         2.7%         .540           Antithomobic reatment         44         31%         51         2.7%         .540           Antithomobic reatment         43         30%         50         2.7%         .540           Antithomobic reatment         43         30%         50         2.7%         .540           Community or non-socormial healthcare essociated         130         9%         14         8%         .686           Cardise profisorsing factor         7         40%         .57         .93%         .833           Timing of IE         2015-2017 (retrospective cohort)         50         .95%         .67         .36         .90%           2015-2017 (retrospective cohort)         50         .36%         .67         .36         .90%           Computing antification         .5         .3%         .3         .2%         .90% <tr< td=""><td>Diabetes mellitus</td><td>43</td><td>30%</td><td>43</td><td>23%</td><td>.165</td></tr<>	Diabetes mellitus	43	30%	43	23%	.165
Maignary (poid args or hematologic)         14         10%         14         7%         555           Deeity         39         27%         37         20%         115           Deeity         39         27%         37         20%         115           Immunosoparesion         12         8%         14         7%         638           Anthomobic or anticogulation treatment         43         30%         50         27%         538           Sating of infector conset           37%         57         30%         682           Community or non-nesocomial healthcare associated         130         9%         14         8%         686           Cardia predisposing factors         74         62%         94         50%         625           Posthetic valve         39         77%         57         30%         53           2018-2022 (prospective ochort)         50         35%         67         36         20         20         30           2018-2022 (prospective schort)         50         35%         67         36         3122         300           Cobagues negitive staphylococi         10         7%         6         3%         3122	Chronic kidney disease (moderate or severe)	18	13%	28	15%	.631
Obesity         39         27%         37         20%         111           Immunoaption         12         8%         14         7%         838           Antithombotic or anticoagulation treatment         72         50%         91         44%         838           Anticogulation treatment         44         31%         51         27%         538           Setting of infection onest	Malignancy (solid organ or hematologic)	14	10%	14	7%	.551
Immunosuppression         12         8%         14         7%         838           Antithrombotic or anticoagulation treatment         24         50%         91         49%         824           Antithrombotic or anticoagulation treatment         43         30%         50         27%         538           Setting of infection onset	Obesity	39	27%	37	20%	.115
Anithrombotic or anticoagulation treatment         72         50%         91         49%         824           Antiformation treatment         44         31%         51         27%         .538           Setting of infection onset	Immunosuppression	12	8%	14	7%	.838
Anithematic treatment         44         31%         51         27%         540           Anticogulation treatment         43         30%         50         27%         533           Setting of infection onset	Antithrombotic or anticoagulation treatment	72	50%	91	49%	.824
Anticoagulation treatment         43         30%         50         27%         .538           Satting of infaction onest	Antithrombotic treatment	44	31%	51	27%	.540
Setting of Infection onset         International onset         International onset           Community or non-roscomial healthcare-associated         130         91%         173         93%           Noscocnial         13         98%         14         85%         668           Cardiac predisposing factors         74         52%         94         50%         825           Prosthetic valve         39         27%         57         30%         543           Trining of IE         2015-202 (prospective cohort)         50         35%         67         36           2016-202 (prospective cohort)         93         65         120         42         .900           Microbiological identification          77         41%         .575         Cocquisate regative staphylococci         35         24%         60         32%         .142           Enterococci         17         12%         21         11%         .863         .265         .356         .343         .265         .356         .345         .300         .32%         .300         .32%         .300         .32%         .300         .32%         .300         .32%         .300         .32%         .300         .32%         .300 <t< td=""><td>Anticoagulation treatment</td><td>43</td><td>30%</td><td>50</td><td>27%</td><td>.538</td></t<>	Anticoagulation treatment	43	30%	50	27%	.538
Community or non-nosoconial healthcare-associated         130         91%         173         93%           Nosoconial         13         91%         14         8%         686           Cardiac predisposing factors         74         62%         94         60%         825           Prosthetic valve         39         27%         57         30%         543           Tirning of IE         2015-2017 fetrospective cohort)         50         35%         67         36           2015-2017 fetrospective cohort)         50         35%         67         36         2015-2017 fetrospective cohort)         50         35%         67         42         .908           Morobiological identification	Setting of infection onset					
Nosocomial         13         9%         14         9%         686           Cardiac predisposing factors         74         52%         94         50%         825           Prosthetic valve         39         27%         57         30%         543           Z015-202 (prospective cohort)         53         65         120         42         968           Microbiogical identification           55         200         42         968           Staphylococcus aureus         64         45%         77         41%         575           Codgulase negative staphylococci         10         7%         6         3%         127           Streptococci         35         24%         60         32%         14           Other gram-positive         5         3%         3         2%         300           HACEK         6         4%         5         3%         24%         300           Intracellular pathogens         0         0%         3         2%         300           Intracellular pathogens         134         94%         175         94%         1000           Polymicrobial infection         4         3%         <	Community or non-nosocomial healthcare-associated	130	91%	173	93%	
The Cardiac predisposing factors         74         52%         94         50%         825           Prosthetic valve         39         27%         57         30%         643           Trining of IE	Nosocomial	13	9%	14	8%	686
Calcular brainpoint grading and grading and grading produption grading and grad	Cardiac predisposing factors	74	52%	9/	50%	825
Training of III         Difference         Di	Prosthetic value	30	27%	57	30%	.020
Image of L         Second	Timing of IE		2770	57	50 %	.040
ACIT - Verticespective control         30         30%         60         30           2018-2022 (prospective control)         93         65         120         42         908           Microbiogical identification         5         77         41%         .575           Cocaguiase negative staphylococci         10         7%         6         3%         .142           Enterococci         35         24%         60         32%         .142           Enterococci         17         12%         21         11%         .863           Other gram-positive         5         3%         3         2%         .300           Intracellular pathogens         0         0%         3         2%         .261           Fungi         2         1%         3         2%         .000         .00%         .63         .2%         .000           Polymicrobial infection         4         3%         8         4%         .66         .00%         .00         .00         .03%         .16         .02%         .000           Polymicrobial infection         4         3%         8         4%         .63         .00%         .64         .00%         .661         .0	2015 2017 (retreapentive schort)	FO	25.0/	67	26	
Cli Back 222 (prospective control of contro do contro of control of control of control of control of control	2019–2017 (renospective cohort)	50	30 % 65	120	42	000
Staphylococci         64         45%         77         41%         575           Cagulase negative staphylococci         10         7%         6         3%         .127           Streptococci         35         24%         60         32%         .142           Enterococci         17         12%         21         11%         .863           Other gram-positive         5         3%         3         2%         .300           HACEK         6         4%         5         3%         .541           Other gram-negative         5         3%         3         2%         .300           Intracellular pathogens         0         0%         3         2%         .261           Fungi         2         1%         3         2%         .000           Polymicrobial infection         4         3%         8         4%         .030           No identification         4         3%         8         4%         .030           Fever         120         84%         153         82%         .661           Heart murmur         90         63%         .116         62%         .909           New heart murmur	Aliorabiological identification	95	05	120	42	.906
Stapnyaccoccus alreus       64       4%       77       41%       5.5         Coagulase negative staphylococci       10       7%       6       33%       1.127         Streptococci       35       24%       60       32%       .142         Enterococci       17       12%       21       11%       .833         Other gram-positive       5       3%       3       2%       .300         IACEK       6       4%       5       3%       .541         Other gram-negative       5       3%       3       .2%       .300         Intracellular pathogens       0       0%       3       .2%       .201         Fungi       2       1%       3       .2%       1.000         Polymicrobial infection       4       3%       8       .4%       .563         Manifestations       5       .3%       16       .62%       .909         Ne identification       4       .3%       8       .4%       .563         Manifestations       120       .84%       .153       .82%       .661         Heart murmur       90       .63%       .116       .62%       .909         <		64	450/	77	410/	575
Coaguase negative staphylococci         10         7%         6         3%         1.12           Streptococci         35         24%         60         32%         1.42           Enterococci         17         12%         21         11%         863           Other gram-nositive         5         3%         3         2%         .300           HACEK         6         4%         5         3%         .541           Other gram-negative         5         3%         3         2%         .300           Intracellular pathogens         0         0%         3         2%         .261           Fungi         2         1%         3         2%         .000           No identification         4         3%         8         4%         .563           Marifestations	Staphylococcus aureus	64	45%	//	41%	.5/5
Streptococci       35       24%       60       32%       1.142         Enterococci       17       12%       21       11%       883         Other gram-positive       5       3%       3       2%       300         HACEK       6       4%       5       3%       544       300         Intracellular pathogens       0       0%       3       2%       300         Intracellular pathogens       0       0%       3       2%       300         Polymicrobial infection       4       3%       2       1%       409         No identification       4       3%       2       1%       409         No identification       4       3%       8       4%       563         Marifestations       134       94%       175       94%       1.000         Fever       120       84%       163       82%       661         Heart murmur       90       63%       116       62%       999         New heart murmur       63       44%       91       49%       437         Immunologic phenomena       10       7%       25       13%       0.072         Seps		10	7%	6	3%	.127
Intercocci         Intercocci <thintercocci< th="">         Intercocci         Intercoc</thintercocci<>	Streptococci	35	24%	60	32%	.142
Other gram-negative         5         3%         3         2%         .300           HACEK         6         4%         5         3%         .541           Other gram-negative         5         3%         3         2%         .300           Intracellular pathogens         0         0%         3         2%         .261           Fungi         2         1%         3         2%         .000           Polymicrobial infection         4         3%         2         1%         .409           No identification         4         3%         8         4%         .563           Manifestations         134         94%         .175         .94%         .000           Fever         120         .84%         .153         .82%         .661           Heart murmur         90         .63%         .116         .62%         .909           New heart murmur         63         .44%         .91         .49%         .437           Immunologic phenomena         10         .7%         .25         .13%         .072           Sepsis         .62         .30%         .92         .49%         .130           Cerebral im	Enterococci	17	12%	21	11%	.863
HACEK       6       4%       5       3%	Other gram-positive	5	3%	3	2%	.300
Other gram-negative         5         3%         3         2%         300           Intracellular pathogens         0         0%         3         2%         .261           Fungi         2         1%         3         2%         .1000           Polymicrobial infection         4         3%         2         1%         .409           No identification         4         3%         8         4%         .563           Manifestations	HACEK	6	4%	5	3%	.541
Intracellular pathogens         0         0%         3         2%         261           Fungi         2         1%         3         2%         1.000           Polymicrobial infection         4         3%         2         1%         4.090           No identification         4         3%         2         1%         4.090           No identification         4         3%         8         4%         .563           Manifestations         5         5         94%         1.000         Fever         120         84%         153         82%         .661           Heart murmur         90         63%         116         62%         .999           New heart murmur         63         44%         91         49%         .437           Immunologic phenomena         10         7%         25         13%         .072           Sepsis         62         43%         92         49%         .317           Septic shock         29         20%         .37         20%         .000           Cerebral imaging performed due to neurologic symptoms         48         34%         127         68%         <.001	Other gram-negative	5	3%	3	2%	.300
Fungi         2         1%         3         2%         1.000           Polymicrobial infection         4         3%         2         1%         .000           No identification         4         3%         8         4%         .563           Mainfestations	Intracellular pathogens	0	0%	3	2%	.261
Polymicrobial infection         4         3%         2         1%         409           No identification         4         3%         8         4%         .563           Manifestations	Fungi	2	1%	3	2%	1.000
No identification         4         3%         8         4%         .563           Manifestations	Polymicrobial infection	4	3%	2	1%	.409
Manifestations           Systemic symptoms         134         94%         175         94%         1.000           Fever         120         84%         153         82%         .661           Heart murmur         90         63%         116         62%         .909           New heart murmur         63         44%         91         49%         .437           Immunologic phenomena         10         7%         25         13%         .072           Sepsis         62         43%         92         49%         .317           Septic shock         29         20%         37         20%         .000           Cerebral imaging performed due to neurologic symptoms         48         34%         127         68%         <.001	No identification	4	3%	8	4%	.563
Systemic symptoms       134       94%       175       94%       1.000         Fever       120       84%       153       82%       .661         Heart murmur       90       63%       116       62%       .909         New heart murmur       63       44%       91       49%       .437         Immunologic phenomena       10       7%       25       13%       .072         Sepsis       62       43%       92       49%       .317         Septic shock       29       20%       37       20%       .001         Deficit       11       8%       71       38%       <.001	Manifestations					
Fever         120         84%         153         82%         .661           Heart murmur         90         63%         116         62%         .909           New heart murmur         63         44%         91         49%         .437           Immunologic phenomena         10         7%         25         13%         .072           Sepsis         62         43%         92         49%         .317           Septic shock         29         20%         37         20%         .000           Cerebral imaging performed due to neurologic symptoms         48         34%         127         68%         <.001	Systemic symptoms	134	94%	175	94%	1.000
Heart murmur         90         63%         116         62%         .909           New heart murmur         63         44%         91         49%         .437           Immunologic phenomena         10         7%         25         .13%         .072           Sepsis         62         43%         92         49%         .317           Septic shock         29         20%         .37         20%         .000           Cerebral imaging performed due to neurologic symptoms         48         34%         127         68%         <.001	Fever	120	84%	153	82%	.661
New heart murmur         63         44%         91         49%         .437           Immunologic phenomena         10         7%         25         13%         .072           Sepsis         62         43%         92         49%         .317           Septic shock         29         20%         37         20%         1.000           Cerebral imaging performed due to neurologic symptoms         48         34%         127         68%         <.001	Heart murmur	90	63%	116	62%	.909
Immunologic phenomena         10         7%         25         13%         .072           Sepsis         62         43%         92         49%         .317           Septic shock         29         20%         37         20%         1.000           Cerebral imaging performed due to neurologic symptoms         48         34%         127         68%         <.001	New heart murmur	63	44%	91	49%	.437
Sepsis         62         43%         92         49%         .317           Septic shock         29         20%         37         20%         1.000           Cerebral imaging performed due to neurologic symptoms         48         34%         127         68%         <.001	Immunologic phenomena	10	7%	25	13%	.072
Septic shock         29         20%         37         20%         1.000           Cerebral imaging performed due to neurologic symptoms         48         34%         127         68%         <.001	Sepsis	62	43%	92	49%	.317
Cerebral imaging performed due to neurologic symptoms         48         34%         127         68%         <.001           Deficit         11         8%         71         38%         <.001	Septic shock	29	20%	37	20%	1.000
Deficit         11         8%         71         38%         <.001           Confusion/coma         31         22%         72         39%         .001           Headache         7         5%         14         7%         .373           Seizures         0         0%         4         2%         .136           Days to cerebral imaging         4         1–8         2         0–5         <.001	Cerebral imaging performed due to neurologic symptoms	48	34%	127	68%	<.001
Confusion/coma         31         22%         72         39%         .001           Headache         7         5%         14         7%         .373           Seizures         0         0%         4         2%         .136           Days to cerebral imaging         4         1–8         2         0–5         <.001	Deficit	11	8%	71	38%	<.001
Headache         7         5%         14         7%         .373           Seizures         0         0%         4         2%         .136           Days to cerebral imaging         4         1-8         2         0-5         <.001           Embolic events prior to cerebral imaging         53         37%         67         36%         .819           Cutaneous         13         9%         17         9%         1.000           Ocular         2         1%         14         7%         .010           Thoracoabdominal         43         30%         55         29%         .904           Site of infection         74         52%         94         50%         .825	Confusion/coma	31	22%	72	39%	.001
Seizures         0         0%         4         2%         .136           Days to cerebral imaging         4         1–8         2         0–5         <.001	Headache	7	5%	14	7%	.373
Days to cerebral imaging         4         1–8         2         0–5         <.001           Embolic events prior to cerebral imaging         53         37%         67         36%         .819           Cutaneous         13         9%         17         9%         1.000           Ocular         2         1%         14         7%         .010           Thoracoabdominal         43         30%         55         29%         .904           Site of infection         74         52%         94         50%         .825	Seizures	0	0%	4	2%	.136
Embolic events prior to cerebral imaging         53         37%         67         36%         .819           Cutaneous         13         9%         17         9%         1.000           Ocular         2         1%         14         7%         .010           Thoracoabdominal         43         30%         55         29%         .904           Site of infection         Acrtic valve         74         52%         94         50%         .825	Days to cerebral imaging	4	1–8	2	0–5	<.001
Cutaneous         13         9%         17         9%         1.000           Ocular         2         1%         14         7%         .010           Thoracoabdominal         43         30%         55         29%         .904           Site of infection         Acrtic valve         74         52%         94         50%         .825	Embolic events prior to cerebral imaging	53	37%	67	36%	.819
Ocular         2         1%         14         7%         .010           Thoracoabdominal         43         30%         55         29%         .904           Site of infection         Aortic valve         74         52%         94         50%         .825	Cutaneous	13	9%	17	9%	1.000
Thoracoabdominal         43         30%         55         29%         .904           Site of infection	Ocular	2	1%	14	7%	.010
Site of infection         74         52%         94         50%         .825	Thoracoabdominal	43	30%	55	29%	.904
Aortic valve 74 52% 94 50% .825	Site of infection					
	Aortic valve	74	52%	94	50%	.825

#### Table 4. Continued

	Wit	thout CEE (n = 143)	V	Vith CEE (n = 187)	Р
Mitral valve	52	36%	105	56%	<.001
Other left-side site of infection	1	1%	1	1%	1.000
Tricuspid valve	18	13%	9	5%	.014
Pulmonary valve	7	5%	1	1%	.023
Multivalvular	17	12%	23	12%	1.000
CIED-IE	14	10%	7	4%	.039
Type of left-side valve					
Native	100	70%	138	74%	.459
Prosthetic	34	24%	52	28%	.449
Positive imaging Duke criterion	115	80%	156	83%	.562
Vegetation	102	71%	141	75%	.450
Vegetation ≥10 mm	61	43%	92	49%	.002
Abscess	27	19%	56	30%	.029
Other lesions <sup>a</sup>	24	17%	42	22%	.214

Data are depicted as number/percentage or median/Q1–Q3.

Abbreviations: CEE, cerebral embolic events; CIED-IE, cardiac implantable electronic device-related infective endocarditis; EE, embolic events; HACEK, Haemophilus spp., Aggregatibacter spp., Cardiobacterium hominis, Eikenella corrodens, Kingella kingae; IE, infective endocarditis.

<sup>a</sup>Perforation, dehiscence of prosthetic valve, fistula, pseudoaneurysm, aneurysm.

CEEs' complications, such as endovascular thrombectomy for ischemic lesions, drainage of abscess, or specific treatment of hemorrhagic lesions or mycotic aneurysms. Such interventions were indicated in 5% of our patients' cohort, which was comparable to previous studies [16, 19]. None of these treatments was found to be indicated among asymptomatic patients with suspected IE, underlining the fact that a policy of systematic Cer-Im in asymptomatic patients with suspected IE is not warranted.

Even though the diagnostic impact of systematic Cer-Im is limited, its impact on patient's management is probably much more important. Indeed, Cer-Im together with the presence of a left-sided valvular vegetation >10 mm, established a new surgical indication for embolism prevention in 22% of IE patients (19% among asymptomatic patients). In the first randomized clinical trial of patients with large vegetations without heart failure, but at high-risk for EEs, early surgery resulted in a significantly lower rate of EEs, as compared to conventional treatment (0% vs 21%; P.005) [20]. Previous studies also reported the influence of Cer-Im on the surgical treatment strategy. In a metanalysis including IE patients, cerebral MRI findings led to changes in the surgical plan in 14% of patients (defined as establishing a new indication, or changes in surgical = planification, including advancement, cancelation or postponement). In the present study, only the establishment of a new surgical indication has been considered as the surgical endpoint.

As previously shown [21], the sensitivity of CT scan and MRI for the detection of hemorrhagic lesions, mycotic aneurysms, or cerebral abscess was comparable, but MRI was far more sensitive than CT scan for the detection of ischemic lesions. This underlines the importance of performing early MRI to accurately detect the whole spectrum of brain lesions potentially associated with IE.

The study has several limitations. First, because the study is a non-interventional one, the influence of Cer-Im on subsequent management was on discretion of the treating physician and infectious diseases specialist. Furthermore, in our center, valve surgery was offered on patients with vegetation >10 mm and EEs even if the EEs occurred before 5 days of appropriate antimicrobial treatment, based on the fact that although the risk of EEs decreases steadily during treatment, it remains high during the first 2 weeks of treatment. Thus, patients could benefit from the prevention of subsequent risk of EEs by an early cardiac surgery [20, 22, 23]; this difference in approach could limit generatability of our results in centers with different surgical practices. Second, cerebral angiography was not systematically performed and some mycotic aneurysms could have remained undiagnosed. Additionally, not all patients had a cerebral MRI, which is more sensitive than CT scan. Third, although we only evaluated the impact of Cer-Im on the establishment of new surgical indications, other important changes in management, such as advancement, cancelation, and postponement were not assessed. Furthermore, the impact of diagnostic or management modification on patient outcomes was not evaluated. Finally, even though Duke criteria were commonly used for the definition of IE, their diagnostic performance is moderate (sensitivity ~80%) and should not replace clinical judgment [24]; thus, a final IE diagnosis was made after 2 months, incorporating endocarditis team appreciation.

In conclusion, our results do not support a policy of systematic Cer-Im in asymptomatic patients with suspected IE for diagnostic purposes, since it failed to substantially reclassify patients according to Duke criteria. On the other hand, together with the presence of a valvular vegetation >10 mm, Cer-Im led to the establishment of a new surgical indication for EEs' prevention in one fifth of patients. Thus, systematic Cer-Im in asymptomatic IE patients may improve decision making, but more studies are needed to elucidate whether such changes in treatment strategy will eventually improve patient's prognosis in terms of a better survival.

#### Supplementary Data

Supplementary materials are available at *Clinical Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

#### Notes

*Author Contributions.* P. M. and B. G. conceived the idea. M. P. O., B. G., N. I., V. D., Y. M., S. P., P. T., and M. K. collected the patients" data. P. M. supervised the project. M. P. O. performed the analysis and interpreted the results. M. P. O. wrote the manuscript. All authors contributed to manuscript revision and read and approved the submitted version.

**Potential conflicts of interest.** The authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.

#### References

- Mohananey D, Mohadjer A, Pettersson G, et al. Association of vegetation size with embolic risk in patients with infective endocarditis: a systematic review and meta-analysis. JAMA Intern Med 2018; 178:502–10.
- Duval X, Iung B, Klein I, et al. Effect of early cerebral magnetic resonance imaging on clinical decisions in infective endocarditis: a prospective study. Ann Intern Med 2010; 152:497–504, W175.
- Champey J, Pavese P, Bouvaist H, et al. Is brain angio-MRI useful in infective endocarditis management? Eur J Clin Microbiol Infect Dis 2016; 35:2053–8.
- Thuny F, Avierinos JF, Tribouilloy C, et al. Impact of cerebrovascular complications on mortality and neurologic outcome during infective endocarditis: a prospective multicentre study. Eur Heart J 2007; 28:1155–61.
- Snygg-Martin U, Gustafsson L, Rosengren L, et al. Cerebrovascular complications in patients with left-sided infective endocarditis are common: a prospective study using magnetic resonance imaging and neurochemical brain damage markers. Clin Infect Dis 2008; 47:23–30.
- Monteiro TS, Correia MG, Golebiovski WF, Barbosa GIF, Weksler C, Lamas CC. Asymptomatic and symptomatic embolic events in infective endocarditis: associated factors and clinical impact. Braz J Infect Dis 2017; 21:240–7.
- Okazaki S, Yoshioka D, Sakaguchi M, Sawa Y, Mochizuki H, Kitagawa K. Acute ischemic brain lesions in infective endocarditis: incidence, related factors, and postoperative outcome. Cerebrovasc Dis 2013; 35:155–62.

- Champey J, Pavese P, Bouvaist H, et al. Cerebral imaging in infectious endocarditis: a clinical study. Infect Dis 2016; 48:235–40.
- Chakraborty T, Scharf E, Rabinstein AA, et al. Utility of brain magnetic resonance imaging in the surgical management of infective endocarditis. J Stroke Cerebrovasc Dis 2017; 26:2527–35.
- Hess A, Klein I, Iung B, et al. Brain MRI findings in neurologically asymptomatic patients with infective endocarditis. AJNR Am J Neuroradiol 2013; 34:1579–84.
- Cooper HA, Thompson EC, Laureno R, et al. Subclinical brain embolization in left-sided infective endocarditis: results from the evaluation by MRI of the brains of patients with left-sided intracardiac solid masses (EMBOLISM) pilot study. Circulation 2009; 120:585–91.
- Iung B, Klein I, Mourvillier B, et al. Respective effects of early cerebral and abdominal magnetic resonance imaging on clinical decisions in infective endocarditis. Eur Heart J Cardiovasc Imaging 2012; 13:703–10.
- Iung B, Tubiana S, Klein I, et al. Determinants of cerebral lesions in endocarditis on systematic cerebral magnetic resonance imaging: a prospective study. Stroke 2013; 44:3056–62.
- Chakraborty T, Scharf E, DeSimone D, et al. Variable significance of brain MRI findings in infective endocarditis and its effect on surgical decisions. Mayo Clin Proc 2019; 94:1024–32.
- Habib G, Lancellotti P, Antunes MJ, et al. 2015 ESC guidelines for the management of infective endocarditis: the task force for the management of infective endocarditis of the European Society of Cardiology (ESC). endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J 2015; 36:3075–128.
- Ahn Y, Joo L, Suh CH, et al. Impact of brain MRI on the diagnosis of infective endocarditis and treatment decisions: systematic review and meta-analysis. AJR Am J Roentgenol 2022; 218:958–68.
- Friedman ND, Kaye KS, Stout JE, et al. Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 2002; 137:791–7.
- Yang A, Tan C, Daneman N, et al. Clinical and echocardiographic predictors of embolism in infective endocarditis: systematic review and meta-analysis. Clin Microbiol Infect 2019; 25:178–87.
- Meshaal MS, Kassem HH, Samir A, Zakaria A, Baghdady Y, Rizk HH. Impact of routine cerebral CT angiography on treatment decisions in infective endocarditis. PLoS One 2015; 10:e0118616.
- Kang DH, Kim YJ, Kim SH, et al. Early surgery versus conventional treatment for infective endocarditis. N Engl J Med 2012; 366:2466–73.
- Vitali P, Savoldi F, Segati F, et al. MRI Versus CT in the detection of brain lesions in patients with infective endocarditis before or after cardiac surgery. Neuroradiology 2022; 64:905–13.
- Scheggi V, Alterini B, Olivotto I, et al. Embolic risk stratification and prognostic impact of early surgery in left-sided infective endocarditis. Eur J Intern Med 2020; 78:82–7.
- Kim DH, Kang DH, Lee MZ, et al. Impact of early surgery on embolic events in patients with infective endocarditis. Circulation 2010; 122:S17–22.
- Habib G, Derumeaux G, Avierinos JF, et al. Value and limitations of the duke criteria for the diagnosis of infective endocarditis. J Am Coll Cardiol 1999; 33: 2023–9.